| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | F2DQF16BXE |
| InChI Key | KKYABQBFGDZVNQ-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C22H26FN3O2 |
| Molecular Weight | 383.47 |
| AlogP | 3.86 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 71.09 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 28.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | MAP kinase p38 alpha inhibitor |
| Primary Target | |
|---|---|
| mitogen-activated protein kinase 14 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Cytochrome P450
Cytochrome P450 family 2
Cytochrome P450 family 2C
Cytochrome P450 2C9
|
- | 31622.78 | - | - | - | |
|
Enzyme
Kinase
Protein Kinase
AGC protein kinase group
AGC protein kinase PKA family
|
- | - | 49278 | - | - | |
|
Enzyme
Kinase
Protein Kinase
CAMK protein kinase group
CAMK protein kinase MAPKAPK family
CAMK protein kinase MAPKAPK subfamily
|
- | - | 27 | - | - | |
|
Enzyme
Kinase
Protein Kinase
CMGC protein kinase group
CMGC protein kinase MAPK family
CMGC protein kinase p38 subfamily
|
- | 25.12-5500 | 29 | 7.2-63.1 | - | |
|
Enzyme
Kinase
Protein Kinase
STE protein kinase group
STE protein kinase STE20 family
STE protein kinase YSK subfamily
|
- | - | 11 | - | - | |
|
Enzyme
Kinase
Protein Kinase
|
- | 25.12-5500 | 11 | 7.2-63.1 | - | |
|
Enzyme
Ligase
|
- | - | 1690 | - | - | |
|
Enzyme
Transferase
|
- | - | - | - | 2.924-14.24 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | -6.14-9.5 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Acute Coronary Syndrome | 3 | D054058 | ClinicalTrials |
| Muscular Dystrophy, Facioscapulohumeral | 3 | D020391 | ClinicalTrials |
| Severe Acute Respiratory Syndrome | 3 | D045169 | ClinicalTrials |
| Glomerulosclerosis, Focal Segmental | 2 | D005923 | ClinicalTrials |
| Pulmonary Disease, Chronic Obstructive | 2 | D029424 | ClinicalTrials |
| Atherosclerosis | 2 | D050197 | ClinicalTrials |
| Arthritis, Rheumatoid | 2 | D001172 | ClinicalTrials |
| Lipid Metabolism Disorders | 2 | D052439 | ClinicalTrials |
| Depressive Disorder, Major | 2 | D003865 | ClinicalTrials |
| Neuralgia | 2 | D009437 | ClinicalTrials |
| Cardiovascular Diseases | 1 | D002318 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 585543-15-3 |
| ChEBI | 131167 |
| ChEMBL | CHEMBL1088752 |
| DrugBank | DB12270 |
| FDA SRS | F2DQF16BXE |
| Guide to Pharmacology | 7835 |
| PubChem | 11552706 |
| SureChEMBL | SCHEMBL1070401 |
| ZINC | ZINC000035793138 |